TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	B4GO9S	2-Ethoxy-N-[[1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56672421	C26H35N3O2	421.6	CCOC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C4=CC=CC=C4	IC50 = 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	B4GO9S	2-Ethoxy-N-[[1-(4-phenylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56672421	C26H35N3O2	421.6	CCOC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C4=CC=CC=C4	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	B4VJ8P	3-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56672532	C23H29N3O2	379.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC(=CC=C4)OC	IC50 = 63095.73 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	B4VJ8P	3-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56672532	C23H29N3O2	379.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC(=CC=C4)OC	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	B5DQ6U	4-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56679227	C23H29N3O2	379.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=C(C=C4)OC	IC50 = 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	B5DQ6U	4-Methoxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56679227	C23H29N3O2	379.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=C(C=C4)OC	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	B5EGS0	3-[(Z)-4-[[(Z)-4-(7,8-Dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[(2S)-2-(3,4-dimethoxyphenyl)propyl]amino]but-2-enyl]-7,8-dimethoxy-1H-3-benzazepin-2-one	Investigative	46939500	C43H51N3O8	737.9	C[C@@H](C1=CC(=C(C=C1)OC)OC)CN(C/C=C\\CN2C(=O)CC3=CC(=C(C=C3C=C2)OC)OC)C/C=C\\CN4C(=O)CC5=CC(=C(C=C5C=C4)OC)OC	EC50 = 135730 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	B6Q1AZ	2-Fluoro-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56665613	C22H26FN3O	367.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=CC=C4F	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BBVU25	2-Ethyl-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56682419	C23H37N3O	371.6	CCC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C(C)C	IC50 = 79432.82 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BBVU25	2-Ethyl-N-[[1-(4-propan-2-ylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56682419	C23H37N3O	371.6	CCC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C(C)C	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BBZ52A	2-Chloro-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	39734391	C19H28ClN3O	349.9	CN1CCN(CC1)C2(CCCCC2)CNC(=O)C3=CC=CC=C3Cl	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BDEY35	2-Hydroxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56675914	C22H27N3O2	365.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=CC=C4O	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BDEY35	2-Hydroxy-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56675914	C22H27N3O2	365.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=CC=C4O	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BEVG30	2-Methoxy-N-[(2-piperidin-1-yl-1,3-dihydroinden-2-yl)methyl]benzamide	Investigative	56658685	C23H28N2O2	364.5	COC1=CC=CC=C1C(=O)NCC2(CC3=CC=CC=C3C2)N4CCCCC4	IC50 = 50118.72 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BEVG30	2-Methoxy-N-[(2-piperidin-1-yl-1,3-dihydroinden-2-yl)methyl]benzamide	Investigative	56658685	C23H28N2O2	364.5	COC1=CC=CC=C1C(=O)NCC2(CC3=CC=CC=C3C2)N4CCCCC4	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BI6KA8	6-[({1-[2-(7-Methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one	Investigative	15982534	C24H28N6O4	464.5	COC1=CC2=C(C=C1)N=CC(=O)N2CCN3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5	IC50 ~ 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BI92LP	2-Chloro-N-[[2-(4-methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]benzamide	Investigative	56672533	C22H26ClN3O	383.9	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=CC=C4Cl	IC50 = 158489.32 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BLV5G7	3-[(Z)-4-[[(Z)-4-(7,8-Dimethoxy-2-oxo-1H-3-benzazepin-3-yl)but-2-enyl]-[2-(3,4-dimethoxyphenyl)ethyl]amino]but-2-enyl]-7,8-dimethoxy-1H-3-benzazepin-2-one	Investigative	46939418	C42H49N3O8	723.9	COC1=C(C=C(C=C1)CCN(C/C=C\\CN2C(=O)CC3=CC(=C(C=C3C=C2)OC)OC)C/C=C\\CN4C(=O)CC5=CC(=C(C=C5C=C4)OC)OC)OC	EC50 = 70670 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BMWG84	6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]-	Investigative	46206000	C23H26FN7O3	467.5	C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5	IC50 ~ 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BO59LW	N-[[2-(4-Methylpiperazin-1-yl)-1,3-dihydroinden-2-yl]methyl]-2-(trifluoromethoxy)benzamide	Investigative	56662156	C23H26F3N3O2	433.5	CN1CCN(CC1)C2(CC3=CC=CC=C3C2)CNC(=O)C4=CC=CC=C4OC(F)(F)F	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BSEF80	Auglurant	Investigative	60168069	C16H12FN5O2	325.3	CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CN=CN=C3	IC50 ~ 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 2	BSEF80	Auglurant	Investigative	60168069	C16H12FN5O2	325.3	CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CN=CN=C3	IC50 ~ 100000 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BT3S2J	2-Methoxy-N-[2-(4-methylpiperazin-1-yl)ethyl]benzamide	Investigative	17616875	C15H23N3O2	277.36	CN1CCN(CC1)CCNC(=O)C2=CC=CC=C2OC	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BX3SJ8	2-Methyl-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56665614	C20H31N3O	329.5	CC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C	IC50 = 63095.73 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BX3SJ8	2-Methyl-N-[[1-(4-methylpiperazin-1-yl)cyclohexyl]methyl]benzamide	Investigative	56665614	C20H31N3O	329.5	CC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCN(CC3)C	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	BZV4C5	2-Methoxy-N-[(1-morpholin-4-ylcyclohexyl)methyl]benzamide	Investigative	16015637	C19H28N2O3	332.4	COC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCOCC3	IC50 = 50118.72 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 1	BZV4C5	2-Methoxy-N-[(1-morpholin-4-ylcyclohexyl)methyl]benzamide	Investigative	16015637	C19H28N2O3	332.4	COC1=CC=CC=C1C(=O)NCC2(CCCCC2)N3CCOCC3	IC50 ~ 199526.23 nM	Poor binder
T99727	Hyperpolarization cyclic nucleotide-gated channel 4	D0J0ZK	MEL57A	Investigative	46937420	C43H51N3O8	737.9	C[C@H](C1=CC(=C(C=C1)OC)OC)CN(C/C=C\\CN2C(=O)CC3=CC(=C(C=C3C=C2)OC)OC)C/C=C\\CN4C(=O)CC5=CC(=C(C=C5C=C4)OC)OC	EC50 = 103780 nM	Poor binder